Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients

Di-Han Liu1,2,3 · Zheng-Hao Ye1,2 · Si Chen1,2 · Xue-Song Sun4 · Jing-Yu Hou1,2 · Ze-Rui Zhao1,2 · Hao Long1,2

Received: 7 July 2019 / Accepted: 12 December 2019 / Published online: 28 December 2019
© The Author(s) 2019

Abstract
Purpose We combined conventional clinical and pathological characteristics and pathological architectural grading scores to develop a prognostic model to identify a specific group of patients with stage I lung adenocarcinomas with poor survival following surgery.

Methods This retrospective study included 198 patients with stage I lung adenocarcinomas recruited from 2004 to 2013. Multivariate analyses were used to confirm independent risk factors, which were checked for internal validity using the bootstrapping method. The prognostic scores, derived from β-coefficients using the Cox regression model, classified patients into high- and low-risk groups. The predictive performance and discriminative ability of the model were assessed by the area under the receiver operating characteristic curve (AUC), concordance index (C-index) and Kaplan–Meier survival analyses.

Results Three risk factors were identified: T2 (rounding of β-coefficients = 81), necrosis (rounding of β-coefficients = 67), and pathological architectural score of 5–6 (rounding of β-coefficients = 58). The final prognostic score was the sum of points. The derived prognostic scores stratified patients into low- (score ≤ 103) and high- (score > 103) risk groups, with significant differences in 5-year overall survival (high vs. low risk: 49.3% vs. 88.0%, respectively; hazard ratio: 4.55; p < 0.001). The AUC for the proposed model was 0.717. The C-index of the model was 0.693.

Conclusion An integrated prognostic model was developed to discriminate resected stage I adenocarcinoma patients into low- and high-risk groups, which will help clinicians select individual treatment strategies.

Keywords Adenocarcinoma · Prognosis · Tumor necrosis · Architectural grade

Introduction
Lung cancer is the leading cause of cancer death in males and the second leading cause of cancer death in females worldwide (Torre et al. 2016). The 5-year survivals of patients with pathological stage IA after surgery are 92%, 86%, and 81% for stages IA1, IA2, and IA3, respectively (Nowak et al. 2016). Among early-stage patients, 23–29.1% develop recurrence despite curative resection (Kelsey et al. 2016).
According to the American Society of Clinical Oncology adjuvant therapy guideline for resected non-small-cell lung cancers (NSCLCs), adjuvant chemotherapy is recommended for patients with stage II A, II B, or III A disease who have undergone complete surgical resection (Kris et al. 2017). However, the indications for postoperative chemotherapy for stage I patients are still controversial (Bradbury et al. 2017). The decision of which stage IB patients to treat with adjuvant chemotherapy is not as clear as in other stages. Additional prognostic markers beyond stage are needed to determine who may be in need of adjuvant chemotherapy or more aggressive treatment approach.

Previous studies have considered various assessment methods, including grading systems based on certain pathological, architectural, or pathological characteristics, and genomic profiling, for investigating stage I NSCLC patients with a high chance of early relapse (Zhao et al. 2015; Kadota et al. 2012; Ooki et al. 2017; Kratz and Jablons 2009). In the present study, we constructed a novel but concise prognostic model based on conventional clinical and pathological characteristics to stratify patients who underwent complete anatomical resection into different risk groups for developing early recurrence. Using the model, we were able to identify a subset of stage I patients with a higher risk of recurrence and poor survival who may be in need of more aggressive adjuvant treatments or closer follow-up strategies.

**Materials and methods**

**Patients**

This study enrolled 198 patients who underwent anatomical resection with systematic lymph node dissection using thoracotomy or video-assisted thoracic surgery, and who were pathologically diagnosed with stage IA or IB invasive lung adenocarcinomas according to the 8th edition staging system (Detterbeck et al. 2017) for lung cancer from 2004 to 2013 at Sun Yat-Sen University Cancer Center, Guangzhou, China. The patients’ clinical information, pathological findings, and prognoses obtained from the hospital database were evaluated retrospectively. The patients were subsequently followed up every 3 months during the first 2 years, every 6 months during the next 3 years, and then annually. Routine chest and upper abdominal computed tomography, with cranial magnetic resonance imaging or positron emission tomography, if applicable, was performed to evaluate the postoperative recurrence during the follow-up. The study protocol was approved by the institutional review board. The IRB approval number was 2013-FXY-048-Department of thoracic.

**Morphological evaluation and grading system**

Invasive adenocarcinomas were classified as lepidic (LEP), acinar (ACN), papillary (PAP), micropapillary (MIP), and solid (SOL) according to the 2015 World Health Organization classification for lung cancer (Travis et al. 2015). The architectural grading system divided growth patterns into three major categories: grade 1 for LEP, grade 2 for ACN and PAP, and grade 3 for MIP and SOL (Zhao et al. 2015). Patients with a pure growth pattern were given an identical grade for both the first and second grades. The final architectural score was the sum of the grades of the two most predominant patterns. The predominant pattern was defined as that present in the highest percentage within the tissue, with the lowest limit set at 30%. Vascular and/or lymphatic invasion and tumor necrosis were observed. The presence of neuron invasion was defined as tumors involving the epineurium in the peri-tumoral tissue. Two pathologists worked together using a multi-headed microscope, and discussed the analyses until agreement was reached.

**Statistical analyses**

Overall survival (OS) was defined as the time of surgery to death. Disease-free survival (DFS) was defined as the interval between resection and the first recurrence. Patients without an event were censored at the end of the follow-up. The survival curves were estimated and compared using the Kaplan–Meier method and log-rank test. Receiver operating characteristic (ROC) curve analyses were adopted for dichotomization according to the DFS. The ROC analyses were used to assess the predictive accuracy of the prognostic model using the area under the curve (AUC) determination. Comparison of paired AUROCs and 95% confidence intervals (CIs) was performed using the nonparametric Delong test. The predicting performance of the model was also evaluated by calculating the concordance index (C-index) which ranges from 0.5 to 1.0, with 0.5 indicating a random chance and 1.0 indicating a perfect ability to correctly discriminate the outcome with the model. Variables with a value of $p < 0.05$ in univariate analyses were subsequently entered into a Cox regression model for multivariate analyses using the backward conditioned method with estimation of the corresponding hazard ratio (HR), 95% confidence interval (CI), and probability $p$ values. All reported $p$ values were two tailed, with $p < 0.05$ considered statistically significant. Statistical analyses were performed using SPSS statistical software for Windows, version 24.0 (IBM, Armonk, NY, USA) and R (https://www.R-project.org) version 3.5.2.
Model development

Patient demographics (age and sex) and clinical and pathological parameters (smoking history, type of surgery, adjuvant chemotherapy, T stage, lymphovascular invasion, necrosis, neuron invasion, and architectural score) were analyzed for possible correlations with the DFS (as more incidents occurred in stage I patients who had received anatomical resection with systematic lymph node dissection, it may better represent the prognoses) using the Cox proportional HR. Covariates with $p < 0.05$ were included in the multivariate model to build the scoring system. The bootstrapping method, resampled to $n = 1000$, was used to check the internal validity and stability of the Cox regression equation (Sauerbrei and Schumacher 1992). The $\beta$-coefficient of the respective log(HR) obtained from the multivariate model was used to derive weighting factors of the prognostic score that were equal to 100* $\beta$-coefficient with rounding. The final prognostic score was the sum of individual scores. The ROC analyses were adopted for the dichotomization of the prognostic score according to outcomes to determine the best splitter threshold.

Results

Patient demographics and survival

The baseline characteristics of the cohort are summarized in Table 1. In total, only 35 patients (17.7%) had a pure tumor growth pattern (6 for MIP/SOL and 29 for ACN/PAP) and 163 patients (83.2%) presented with mixed growth patterns. There were 89 (44.9%), 31 (15.7%) and 72 (36.4%) patients who scored 3, 4 and 5 in pathological architectural score, respectively. None of the 198 patients received neo-adjuvant chemotherapy. The median follow-up interval was 44.67 months (range 6.23–101.53 months), and 73 patients (36.1%) had documented recurrence and 33 patients (16.7%) died during follow-up. The 5-year OS and DFS across the entire cohort were 78.7% and 57.8%, respectively.

Prognostic scoring system

To develop the model, we first tested the covariates listed in Table 1 for their association with DFS in the cohort. Significant predictors of DFS in univariate analyses are shown in Table 2. Smoking history, sex, T stage, lymphovascular invasion, necrosis, and pathological architectural scores were included in the multivariate analyses. Then the bootstrapping method (resampled to $n = 1000$) was performed, which resulted in highly consistent and stable risk factors (Table 2). In summary, T stage (HR: 2.25; 95% CI 1.41–3.60; $p = 0.001$), necrosis (HR: 1.95; 95% CI 1.15–3.30; $p = 0.013$), and architectural score (HR: 1.79; 95% CI 1.09–2.94; $p = 0.021$) were the key prognostic predictors. Then a scoring model based on weighting (derived by the $\beta$-coefficient of the respective log(HR)) of the three significant covariates was constructed. The score for each covariate is listed in Table 3. The prognostic score (range 0–206) was calculated for each patient. Dichotomization into the low- and high-risk subgroups was based on a cutoff value determined by the ROC analyses predicting the outcomes of 103 points. The AUC for the prognostic score model was 0.717, which was greater than the T stage (AUC: 0.624), architectural score (AUC: 0.611), and necrosis (AUC: 0.617) as shown in Fig. 1. The 95% confidence interval of AUC and the $p$ value are listed in Supplement Table 1. The C-index for the established model to predict DFS was 0.693. Kaplan–Meier curves revealed a significant survival difference between the

| Characteristics | Number of patients (%) |
|-----------------|------------------------|
| Age, years (range) | 60.4 (29–81) |
| Median (range) | |
| Gender | |
| Male | 95 (48.0%) |
| Female | 103 (52.0%) |
| Smoking history | |
| No | 122 (61.6%) |
| Yes | 76 (38.4%) |
| T stage | |
| T1 | 126 (63.6%) |
| T2 | 72 (39.4%) |
| Architectural score | |
| 3–4 | 120 (60.6%) |
| 5–6 | 78 (39.4%) |
| Lymphovascular invasion | |
| No | 111 (56.1%) |
| Yes | 87 (43.9%) |
| Neuron invasion | |
| No | 179 (90.4%) |
| Yes | 19 (9.6%) |
| Necrosis | |
| No | 154 (77.8%) |
| Yes | 44 (22.2%) |
| Type of surgery | |
| Open | 143 (72.2%) |
| VATS | 55 (27.8%) |
| Adjuvant chemotherapy | |
| No | 148 (74.7%) |
| Yes | 50 (25.3%) |

VATS video-assisted thoracic surgery

*According to the 8th edition of UICC/AJCC staging system
low- and high-risk subgroups in both OS and DFS across the entire cohort (Fig. 2). As shown in Fig. 3, the risk model stratified the Kaplan–Meier curves for OS and DFS into the low- and high-risk subgroups of stages Ia and Ib. Importantly, the pathological stage (Ia and Ib) did not differentiate survival curves within a single-risk group.

**Discussion**

Patients with early-stage NSCLC after complete surgical resection are at substantial risk for recurrence. The role of adjuvant chemotherapy for stage I patients is still controversial because previous randomized trials have not reported consistent results (Kris et al. 2017; Bradbury et al. 2017). In daily practice, the tumor–node–metastasis (TNM) system is used to differentiate the prognoses of patients with NSCLC. However, patients with the same TNM stage may have completely different outcomes (Chansky et al. 2009). Because of the heterogeneous nature of NSCLC, it would be imprecise to predict survival using the TNM staging system alone. For this reason, various studies have identified early-stage NSCLCs with poor survival that could potentially benefit from adjuvant treatment.

In our study, the presence of necrosis had significant prognostic implications, in line with previous studies (Makinen et al. 2017; Qian et al. 2018; Yi et al. 2018; Li et al. 2017; Yoshizawa et al. 2011). One of the possible reasons for this
may be that the process of tumor necrosis may release pro-inflammatory intracellular contents into the tumor micro-environment, inducing an inflammatory response involving a diverse set of immune cells such as neutrophils. Tumor-associated neutrophils are associated with poor prognoses in a variety of cancer types, and a previous study reported consistently increased levels of necrosis and infiltration of neutrophils (Li et al. 2017). Another explanation is that most SOL and MIP adenocarcinomas are correlated with the presence of tumor necrosis, with SOL adenocarcinomas showing the highest indices (Makinen et al. 2017). Similar results were found in our study: in 44 adenocarcinomas with necrosis, 25 had SOL and MIP patterns (p = 0.009).

In a previous study (Zhao et al. 2015), we validated the prognostic effects of the grading system for stage I adenocarcinomas in an Asian population. In addition, patients with high-grade components were at higher risk for local–regional recurrence following sublobar resection, so adjuvant therapy may be needed for these patients, even in the early stages (Zhao et al. 2018).

Kadota et al. (2012) proposed a grading system that combined the predominant growth pattern and the mitotic count in ten high-power fields (HPFs). Adenocarcinomas with an intermediate architectural grade (ACN or PAP) with a low (< 3/10 HPFs) mitotic count were classified as low grade. Intermediate architectural grade with intermediate–high mitotic counts was considered intermediate grade and high architectural grade with any mitotic count was classified as high grade. The combination of the architectural grade and the mitotic count also stratified stage I lung adenocarcinomas into different risk groups of recurrence. However, Barletta et al. (2010) did not recognize mitotic count as a significant prognostic factor.

Previous studies of prognostic signatures of genetic expressions (Shedden et al. 2008; Chen et al. 2007; Kratz et al. 2012; Wistuba et al. 2013) have identified two molecular prognostic markers for lung adenocarcinoma (Kratz et al. 2012; Wistuba et al. 2013), but their accuracy in predicting survival is limited. Li et al. (2017) proposed an individualized prognostic signature for non-squamous NSCLC based on immune-related gene pairs along with clinical factors, but its clinical utility also needs to be further tested and validated. Martinez-Terroba et al. (2018) proposed a prognostic signature based on three proteins (BRCA1, QKI, and SLC2A1) to stratify early-stage lung adenocarcinoma patients. Taken together, these studies have illustrated the importance of genetic aspects in predicting prognoses of lung adenocarcinomas. However, considering the additional cost of various genes selected from different studies, which may not be generalized in different populations, the actual clinical utilization of these genetic profiling methods still remains limited in daily clinical practice.

| Variables | Hazard ratio | $\beta$ [HR = $\exp(\beta)$] | Score$^b$ |
|-----------|-------------|------------------------------|---------|
| T stage$^a$ |             |                              |         |
| T1        | 1           | 0                            | 0       |
| T2        | 2.254       | 0.813                        | 81      |
| Architectural score | | | |
| 3–4       | 1           | 0                            | 0       |
| 5–6       | 1.792       | 0.583                        | 58      |
| Necrosis  |             |                              |         |
| No        | 1           | 0                            | 0       |
| Yes       | 1.951       | 0.668                        | 67      |

Hazard ratios estimated by Cox proportional hazards regression

$^a$According to the 8th edition of UICC/AJCC staging system

$^b$Score = 100*$\beta$ with rounding

Fig. 1 Receiver operating characteristic curve and accuracy of the prognostic score system, architectural score, T stage and necrosis
In this study, we identified a novel and practical prognostic model based on morphological features and the TNM stage of patients who underwent anatomical resection of stage I adenocarcinomas. The predictive ability of this model is higher than that of TNM staging and pathological architectural score, with a greater AUC. Stratifying pathological stage I patients into high- and low-risk subgroups for predicting early relapses might have an important impact on individualized treatment strategies.

The limitations of our study included its retrospective nature and the small size of the cohort, which also prevented us from developing an external validation cohort. The model also failed to incorporate other clinical and pathological prognostic factors (e.g., tumor markers, PET–CT value, and central or peripheral tumor) and some important recognized prognostic molecular factors (e.g., KRAS mutations, EGFR mutations, and ALK rearrangements). Incorporation of other prognostic factors may improve this model. Further studies are also needed to validate this prognostic model to assess its real efficacy and to better analyze its utility in clinical practice and trials.

In conclusion, we developed a prognostic model based on morphological features and TNM stage for stage I lung adenocarcinoma patients. We were able to identify low- and high-risk subgroups of stage I patients after surgery, which may help clinicians select individual treatments and management strategies.
Acknowledgements The current study was supported by the Foundation for Science and Technology Research Project of Guangdong Grant (2014B020212014).

Author contributions Conception and design were done by D-HL, Z-RZ, and HL. D-HL, Z-HY, SC, J-YH, Z-RZ, and HL provided the study materials or patients. D-HL, Z-HY and SC collected and assembled the data. Data analyses and interpretation were done by D-HL, Z-RZ and X-SS. Manuscript was written and finally approved by all authors.

Compliance with ethical standards

Conflict of interest The author(s) claimed no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Barletta JA, Yeap BY, Chirieac LR (2010) Prognostic significance of grading in lung adenocarcinoma. Cancer 116(3):659–669
Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis PM (2017) Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review. Clin Lung Cancer 18(3):259–273.e258
Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P (2009) The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4(7):792–801
Chen HY, Yu SL, Chen CH et al (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356(1):11–20
Detterbeck FC, Botfa DI, Kim AW, Tanoue LT (2017) The eighth edition lung cancer stage classification. Chest 151(1):193–203.
Kadota K, Suzuki K, Kachala SS et al (2012) A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 25(8):1117–1127
Kelsey CR, Higgins KA, Peterson BL et al (2013) Local recurrence after surgery for non-small cell lung cancer: a recursive partitioning analysis of multi-institutional data. J Thorac Cardiovasc Surg 146(4):768–773.e671
Krutz JR, Jablons DM (2009) Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer 10(3):151–157
Krutz JR, He J, Van Den Eeden SK et al (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379(9818):823–832
Kris MG, Gaspar LE, Chaff JE et al (2017) adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol 35(25):2960–2974
Li B, Cui Y, Diehn M, Li R (2017) Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 3(11):1529–1537
Makinen JM, Laitakari K, Johnson S et al (2017) Histological features of malignancy correlate with growth patterns and patient outcome in lung adenocarcinoma. Histopathology 71(3):425–436
Martinez-Terroba E, Behrens C, de Miguel EJ et al (2018) A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients. J Thoral 245(4):421–432
Nowak AK, Chansky K, Rice DC, et al (2016) TheIASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol 11(12):2089–2099
Ooki A, Maleki Z, Tsay JJ et al (2017) A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA. Clin Cancer Res 23(22):7141–7152
Qian F, Yang W, Wang R et al (2018) Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. J Thorac Cardiovasc Surg 155(3):1227–1235.e1222
Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11(16):2093–2109
Sheelden K, Taylor JM, Einkemann SA et al (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14(8):822–827
Sica G, Yoshizawa A, Sima CS et al (2010) A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 34(8):1155–1162
Taylor MD, Nagji AS, Bhambidipati CM et al (2012) Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg 93(6):1813–1820
Torre LA, Siegel RL, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1–19
Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–1260
Wistuba II, Behrens C, Lombardi F et al (2013) Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 19(22):6261–6271
Yi E, Bae MK, Cho S, Chung JH, Jeon S, Kim K (2018) Pathological prognostic factors of recurrence in early stage lung adenocarcinoma. ANZ J Surg 88(4):327–331
Yoshizawa A, Motoi N, Riely GJ et al (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24(5):653–664
Zhaor ZR, Xi SY, Li W et al (2015) Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinoma. Lung cancer 90(3):604–609
Zhaor ZR, Lau RWH, Long H et al (2018) Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma. J Thorac Cardiovasc Surg 156(6):2310–2318.e2312

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.